Georgios Skretas, PhD
Bachelor’s degree from the School of Chemical Engineering, National Technical University of Athens (Greece); PhD in Chemical and Biological Engineering from Princeton University (USA)
Biomolecular engineering, synthetic biology, chemical biology, enzyme discovery and engineering, discovery and development of next-generation antibiotics
Description
New member of the ICTER ISC for the term 2024-2028, Dr. Georgios Skretas worked as a post-doctoral research associate at the Institute of Cell and Molecular Biology of the University of Texas at Austin (USA) (2006-2009). In 2010, he received a Marie Curie International Reintegration Fellowship to return to Greece and establish his independent research group in his home country. During 2010-2022, he served as Head of the Laboratory of Enzyme and Synthetic Biotechnology and the Institute of Chemical Biology of the National Hellenic Research Foundation (Greece). Since 2022, he is the Director of the Institute for Bio-innovation at the Biomedical Sciences Research Center “Alexander Fleming” (BSRC Fleming). Georgios Skretas has been awarded a Consolidator Grant by the European Research Council (ERC) (2019-2024) and a grant by the European Commission to establish an ERA Chair in Biomolecular Engineering and Synthetic Biology at BSRC Fleming (2023-2027). He is inventor in four (4) patents/patent applications. He is the Founder and Chief Executive Officer of ResQ Biotech, a spin-off company applying synthetic biology approaches to advance early-stage drug discovery against diseases caused by protein misfolding.
Publication list
- Tsekrekou, M., Giannakou, M., Papanikolopoulou, K., Skretas, G.* 2024. Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS. Frontiers in Molecular Biosciences. 11:1383453.
- Papadopoulou D, Mavrikaki V, Charalampous F, Tzaferis C, Samiotaki M, Papavasileiou KD, Afantitis A, Karagianni N, Denis MC, Sanchez J, Lane JR, Faidon Brotzakis Z, Skretas G, Georgiadis D, Matralis AN*, Kollias G*. 2024. Discovery of the First-in-Class Inhibitors of Hypoxia Up-Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast Activation. Angewandte Chemie Int Ed Engl. 63(14):e202319157.
- Vasilopoulou, Ε., Chroumpi, T., Skretas, G.* 2023. Escherichia coli strains with precise domain deletions in the ribonuclease RNase E can achieve greatly enhanced levels of membrane protein production. Protein Science. 33(2):e4864.
- Vasilopoulou, Ε., Giannakopoulou, A., Kapsalis, H., Michou, M., Michoglou-Sergiou, A., Kolisis, F.N., Skretas, G.* 2022. Second-generation Escherichia coli SuptoxR strains for further enhanced production of recombinant membrane proteins in bacteria. ACS Synthetic Biology. 11, 8, 2599–2609.
- Delivoria, D.C. and Skretas, G.* 2022. Advancing the discovery of chemical rescuers of pathogenic protein misfolding and aggregation by integrating SICLOPPS technology and ultrahigh-throughput screening in bacteria. Methods in Molecular Biology. 2371:215-246.
- Skretas, G.* and Ventura, S.* 2020. Protein Aggregation and Solubility in Microorganisms (Archaea, Bacteria and Unicellular Eukaryotes): Implications and Applications. Frontiers in Microbiology. 11:620239.
- Michou, M., Stergios, A., Skretas, G.* 2020. 0: A second-generation Escherichia coli strain achieving further enhanced recombinant membrane protein production. Biotechnology and Bioengineering. 1–12.
- Michou, M., Delivoria, D.C., Skretas, G.* 2020. High-level production of recombinant membrane proteins using the engineered Escherichia coli Strains SuptoxD and SuptoxR. Bio-protocol. 10(15).
- Delivoria, D. C., Chia S., Habchi, J., Perni, M., Matis, I., Papaevgeniou, N., Chondrogianni, N., Dobson, C. M., Vendruscolo, M., Skretas, G.* 2019. Bacterial production and direct functional screening of expanded molecular libraries for discovering inhibitors of protein aggregation. Science Advances. 5:eaax5108.
- Michou, M., Kapsalis, C., Pliotas, C., Skretas, G.* 2019. Optimization of recombinant membrane protein overexpression in the engineered Escherichia coli strains SuptoxD and SuptoxR. ACS Synthetic Biology. 8(7):1631-1641.
- Zarafeta, D., Galanopoulou, A., Kaili, S., Chegkazi, M.S., Chrysina, E.D., Kolisis, F.N., Hatzinikolaou, D.G.*, Skretas, G.* 2020. XynDZ5: A new thermostable GH10 xylanase. Frontiers in Microbiology. 11:545.
- Kostelidou, K., Matis, M., and Skretas, G*. 2018. Microbial genetic screens and selections for monitoring protein misfolding: tools for the identification of disease-relevant genes and the discovery of potential therapeutic compounds against neurodegenerative diseases. Current Pharmaceutical Design. 24(19):2055-2075.
- Matis, I., Delivoria, D.C., Mavroidi, B., Papaevgeniou, N., Panoutsou, S., Bellou, S., Papavasileiou, K.D., Linardaki, Z., Stavropoulou, A.V., Vekrellis, K., Boukos, N., Kolisis, F.N., Gonos, E.S., Margarity, M., Papadopoulos, M.G., Efthimiopoulos, S., Pelecanou, M., Chondrogianni, N., Skretas, G*. 2017. An integrated bacterial system for the discovery of chemical rescuers of disease-associated protein misfolding. Nature Biomedical Engineering. 1, 838–852.
- Gialama, D., Delivoria, D.C., Michou, M., Giannakopoulou, A., Skretas, G*. 2017. Functional requirements for DjlA- and RraA-mediated enhancement of recombinant membrane protein production in the engineered coli strains SuptoxD and SuptoxR. Journal of Molecular Biology. 429(12):1800-1816.
- Gialama, D., Kostelidou, K., Michou, M., Delivoria, D.C., Kolisis, F.N., Skretas, G*. 2017. Development of Escherichia coli strains that withstand membrane protein-induced toxicity and achieve high-level recombinant membrane protein production. ACS Synthetic Biology. 6(2): 284-300.
